DUBLIN, April 25, 2013 /PRNewswire/ --
Research and Markets has announced the addition of the "Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech, 3rd Edition" report to their offering.
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:
- In-depth understanding of preclinical stage deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of preclinical stage agreements with numerous real life case studies
- Detailed access to actual preclinical stage deals entered into by the leading fifty big pharma and big biotech companies
|SOURCE Research and Markets|
Copyright©2012 PR Newswire.
All rights reserved